

# Ilias Goranitis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1411668/publications.pdf>

Version: 2024-02-01

40  
papers

865  
citations

430874

18  
h-index

501196

28  
g-index

40  
all docs

40  
docs citations

40  
times ranked

1484  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genomic sequencing for the diagnosis of childhood mitochondrial disorders: a health economic evaluation. <i>European Journal of Human Genetics</i> , 2022, 30, 577-586.	2.8	9
2	The Value of Genomic Testing: A Contingent Valuation Across Six Child- and Adult-Onset Genetic Conditions. <i>Pharmacoeconomics</i> , 2022, 40, 215-223.	3.3	6
3	Is faster better? An economic evaluation of rapid and ultra-rapid genomic testing in critically ill infants and children. <i>Genetics in Medicine</i> , 2022, 24, 1037-1044.	2.4	18
4	The value of genomic sequencing in complex pediatric neurological disorders: a discrete choice experiment. <i>Genetics in Medicine</i> , 2021, 23, 155-162.	2.4	13
5	The clinical utility of exome sequencing and extended bioinformatic analyses in adolescents and adults with a broad range of neurological phenotypes: an Australian perspective. <i>Journal of the Neurological Sciences</i> , 2021, 420, 117260.	0.6	16
6	Preferences and values for rapid genomic testing in critically ill infants and children: a discrete choice experiment. <i>European Journal of Human Genetics</i> , 2021, 29, 1645-1653.	2.8	12
7	New evidence on the impact of the Great Recession on health-compromising behaviours. <i>Economics and Human Biology</i> , 2021, 41, 100980.	1.7	2
8	Cost-Effectiveness of Targeted Exome Analysis as a Diagnostic Test in Glomerular Diseases. <i>Kidney International Reports</i> , 2021, 6, 2850-2861.	0.8	15
9	Exome Sequencing for Isolated Congenital Hearing Loss: A Cost-Effectiveness Analysis. <i>Laryngoscope</i> , 2021, 131, E2371-E2377.	2.0	5
10	Rapid exome sequencing and adjunct RNA studies confirm the pathogenicity of a novel homozygous <i>ASNS</i> splicing variant in a critically ill neonate. <i>Human Mutation</i> , 2020, 41, 1884-1891.	2.5	8
11	A cost-effectiveness analysis of genomic sequencing in a prospective versus historical cohort of complex pediatric patients. <i>Genetics in Medicine</i> , 2020, 22, 1986-1993.	2.4	25
12	Mapping the Minnesota Living with Heart Failure Questionnaire (MLHFQ) onto the Assessment of Quality of Life 8D (AQoL-8D) utility scores. <i>Quality of Life Research</i> , 2020, 29, 2815-2822.	3.1	6
13	Validity and Responsiveness of Preference-Based Quality-of-Life Measures in Informal Carers: A Comparison of 5 Measures Across 4 Conditions. <i>Value in Health</i> , 2020, 23, 782-790.	0.3	16
14	The personal utility and uptake of genomic sequencing in pediatric and adult conditions: eliciting societal preferences with three discrete choice experiments. <i>Genetics in Medicine</i> , 2020, 22, 1311-1319.	2.4	31
15	Clinical genomic testing: what matters to key stakeholders?. <i>European Journal of Human Genetics</i> , 2020, 28, 866-873.	2.8	19
16	Parental health spillover effects of paediatric rare genetic conditions. <i>Quality of Life Research</i> , 2020, 29, 2445-2454.	3.1	28
17	Progesterone to prevent miscarriage in women with early pregnancy bleeding: the PRISM RCT. <i>Health Technology Assessment</i> , 2020, 24, 1-70.	2.8	23
18	Antibiotic prophylaxis in the surgical management of miscarriage in low-income countries: a cost-effectiveness analysis of the AIMS trial. <i>The Lancet Global Health</i> , 2019, 7, e1280-e1286.	6.3	7

#	ARTICLE	IF	CITATIONS
19	A head-to-head evaluation of the diagnostic efficacy and costs of trio versus singleton exome sequencing analysis. <i>European Journal of Human Genetics</i> , 2019, 27, 1791-1799.	2.8	37
20	A cost-effectiveness model of genetic testing and periodical clinical screening for the evaluation of families with dilated cardiomyopathy. <i>Genetics in Medicine</i> , 2019, 21, 2815-2822.	2.4	35
21	A Randomized Trial of Progesterone in Women with Bleeding in Early Pregnancy. <i>New England Journal of Medicine</i> , 2019, 380, 1815-1824.	27.0	107
22	A Randomized Trial of Prophylactic Antibiotics for Miscarriage Surgery. <i>New England Journal of Medicine</i> , 2019, 380, 1012-1021.	27.0	16
23	Comprehensive evaluation of a prospective Australian patient cohort with suspected genetic kidney disease undergoing clinical genomic testing: a study protocol. <i>BMJ Open</i> , 2019, 9, e029541.	1.9	6
24	Prophylactic antibiotics to reduce pelvic infection in women having miscarriage surgery â€” The AIMS (Antibiotics in Miscarriage Surgery) trial: study protocol for a randomized controlled trial. <i>Trials</i> , 2018, 19, 245.	1.6	6
25	Cost-Effectiveness of Treatments for the Management of Bone Metastases: A Systematic Literature Review. <i>Pharmacoeconomics</i> , 2018, 36, 301-322.	3.3	15
26	A pilot feasibility randomised controlled trial of an adjunct brief social network intervention in opiate substitution treatment services. <i>BMC Psychiatry</i> , 2018, 18, 8.	2.6	12
27	Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the <sc>TRAPEZE</sc> trial (<sc>ISRCTN</sc> 12808747). <i>BJU International</i> , 2017, 119, 522-529.	2.5	18
28	Maximizing Health or Sufficient Capability in Economic Evaluation? A Methodological Experiment of Treatment for Drug Addiction. <i>Medical Decision Making</i> , 2017, 37, 498-511.	2.4	26
29	Aerobic exercise for vasomotor menopausal symptoms: A cost-utility analysis based on the Active Women trial. <i>PLoS ONE</i> , 2017, 12, e0184328.	2.5	5
30	Testing and Treating Women after Unsuccessful Conservative Treatments for Overactive Bladder or Mixed Urinary Incontinence: A Model-Based Economic Evaluation Based on the BUS Study. <i>PLoS ONE</i> , 2016, 11, e0160351.	2.5	6
31	The validity and responsiveness of the ICECAP-A capability-well-being measure in women with irritative lower urinary tract symptoms. <i>Quality of Life Research</i> , 2016, 25, 2063-2075.	3.1	22
32	Measuring Health and Broader Well-Being Benefits in the Context of Opiate Dependence: The Psychometric Performance of the ICECAP-A and the EQ-5D-5L. <i>Value in Health</i> , 2016, 19, 820-828.	0.3	32
33	Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both. <i>JAMA Oncology</i> , 2016, 2, 493.	7.1	78
34	Bladder ultrasonography for diagnosing detrusor overactivity: test accuracy study and economic evaluation. <i>Health Technology Assessment</i> , 2016, 20, 1-150.	2.8	25
35	TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer. <i>Health Technology Assessment</i> , 2016, 20, 1-288.	2.8	29
36	Economic evaluation alongside factorial trials: a systematic review of empirical studies. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 801-811.	1.4	6

#	ARTICLE	IF	CITATIONS
37	Health care financing and the sustainability of health systems. <i>International Journal for Equity in Health</i> , 2015, 14, 80.	3.5	73
38	Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer. (ISRCTN 12808747) TRAPEZE.. <i>Journal of Clinical Oncology</i> , 2015, 33, e16108-e16108.	1.6	2
39	Health policy making under information constraints: An evaluation of the policy responses to the economic crisis in Greece. <i>Health Policy</i> , 2014, 117, 279-284.	3.0	20
40	An investigation into the construct validity of the Carer Experience Scale (CES). <i>Quality of Life Research</i> , 2014, 23, 1743-1752.	3.1	30